The Pulse
The FDA just voted to crack the peptide market open.
On July 23, the FDA’s compounding advisory committee voted 8 to 6 to recommend adding BPC-157 and KPV to the pharmacy compounding lists, with TB-500 and MOTS-C also favored.
It did this over the explicit objections of the FDA’s own career scientists.
The vote is a recommendation, not a final rule. But it points a whole category of injectables from the gray market toward legitimate telehealth channels.
This is the same door semaglutide walked through in 2023. If you sell injectables, a second wave is forming right now.
The other half of the reshuffle lands July 30.
The FDA’s final decision on whether to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is due this Thursday.
One category opens the same week another possibly closes.
If your unit economics still lean on compounded GLP-1, that supply is on a clock at the exact moment peptides step into the spotlight.
Plan the migration and the expansion together, not one after the other.
Hims is buying its way out of single-category risk.
Hims acquired Eucalyptus in a $1.15B deal and sent its chief medical officer to testify at the peptide hearing.
The company that got squeezed when the FDA called the shortage over is not waiting around to get squeezed again.
The read for smaller brands: the category leader is paying for durable, licensable lines, not another burst of top-of-funnel. Retention is what makes a line durable.
The Deep Dive
The peptide gold rush is about to start. It will be won on retention, not acquisition.
Think back to late 2024.
More than 80 founders with a website and a compounding partner launched a GLP-1 clinic in a matter of months.
The same thing is about to happen with peptides. Analysts already expect a flood of copycat sites the moment the rules clear.
Here is how that plays out, based on how the GLP-1 wave actually went:
The category floods. CAC climbs as everyone bids on the same patient.
Within about six months, the well-funded platforms out-compete the fly-by-night sites on price and credibility.
The small players either get bought or quietly die.
The brands still standing at the end of that window are not the ones who acquired fastest.
They are the ones who kept the patients they acquired.
Because in a land grab, acquisition margin gets bid down to nothing. Retention is the only economics left.
We have watched this in GLP-1 for two years. The brands pulling 25 to 40% of revenue from lifecycle are not the ones with the cheapest ads. They are the ones whose month-1 patients still convert into month 6.
And peptides are harder to retain than GLP-1, not easier.
Patients stack, and stacking breeds doubt.
A GLP-1 patient takes one shot a week. Built-in ritual, single finish line.
A peptide patient often runs three or four compounds at once. No ritual, no clear endpoint.
The science is murky and the long-term safety data on those combinations barely exists.
That means more questions, more second-guessing, and more “am I even doing this right” churn, and it peaks early, the same way GLP-1 doubt spikes around the month 3 plateau.
The education gap is a retention gap.
When a confused peptide patient Googles their protocol, they find Reddit threads and gray-market forums, not you.
Whoever owns the education owns the renewal.
So the move is not to bolt peptides onto your ad account and hope. It is to build the retention layer before the spend:
A format-specific onboarding flow that explains the protocol and sets expectations, front-loaded into the first 12 hours.
A stacking guide framed as clinical guidance, not a cross-sell.
Program-style packaging (a fixed 3 to 6 month protocol billed monthly) so the perceived commitment is the outcome, not the next charge. That structure holds patients better than any discount.
The brands that treated GLP-1 retention as an afterthought spent 2025 refilling a leaky bucket at Q4 ad prices.
The peptide wave is a chance to build the bucket first.
Takeaway: if peptides are on your roadmap, the retention and education layer is the first build, not the last one you get to.
Quick Takes
The new category will not save a leaky base.
Every founder chasing the peptide headline still has a GLP-1 base churning underneath them.
A second category does not fix month-1 drop-off. It doubles it across two product lines.
Fix the retention you already own before you go acquire retention problems somewhere new.
Compliance is quietly becoming a retention feature.
The investors funding this wave keep repeating one word: compliance. Sterile, verified, correctly dosed, doctor-led.
That is not only a legal position, it is a trust position. Patients renew with the brand they believe is keeping them safe.
In a category with murky science, “we do this properly” is a retention message, not just a disclaimer.
One Thing to Try
Before you add a single new treatment line, pull your last 90 days of cancellations for the line you already run.
Sort them by stated reason.
If “not sure it’s working” or “too confusing” outranks “too expensive,” you do not have a pricing problem. You have an education and expectations problem.
That gap is exactly what a multi-compound peptide protocol will widen.
Write one day-14 check-in email that addresses the top confusion for your current treatment, and watch whether saves climb before you touch anything else. Takes under an hour.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.